The cancer has been categorized into three therapeutic groups: ER - ER+ patients receive endocrine therapy, HER – HER+ group is treated by therapeutic targeting of HER/ERBB2, and TNBC - lacking expression of ER, PR, HER receptors2. Here, ESR1 is linked to cancer.